Recent studies on retatrutide, a dual activator for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, indicate encouraging findings in treating obesity and type 2 diabetic condition. Initial information from clinical trials point to considerable decreases in body mass and